AbbVie (ABBV) has risen sharply, recording gains of 5.52% in the past 4 weeks. However, the stock has corrected -1.31% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.1% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has recorded a 20-day Moving Average of 3.03% and the 50-Day Moving Average is 3.22%.
AbbVie (NYSE:ABBV): The stock opened at $63.82 on Friday but the bulls could not build on the opening and the stock topped out at $64.17 for the day. The stock traded down to $63.13 during the day, due to lack of any buying support eventually closed down at $63.32 with a loss of -0.47% for the day. The stock had closed at $63.62 on the previous day. The total traded volume was 8,827,486 shares.
The company Insiders own 0.11% of AbbVie shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.87% . Institutional Investors own 66.71% of AbbVie shares. During last six month period, the net percent change held by insiders has seen a change of -14.58%. In a related news, The Securities and Exchange Commission has divulged that Schumacher Laura J, Officer (Executive Vice President) of AbbVie Inc., had unloaded 186,106 shares at an average price of $60.07 in a transaction dated on June 24, 2016. The total value of the transaction was worth $11,179,387.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.